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The normal low-density lipoprotein (LDL) cholesterol range is 50 to 70 mg/dl for native
hunter-gatherers, healthy human neonates, free-living primates, and other wild mammals (all
of whom do not develop atherosclerosis). Randomized trial data suggest atherosclerosis
progression and coronary heart disease events are minimized when LDL is lowered to 70
mg/dl. No major safety concerns have surfaced in studies that lowered LDL to this range of
50 to 70 mg/dl. The current guidelines setting the target LDL at 100 to 115 mg/dl may lead
to substantial undertreatment in high-risk individuals. (J Am Coll Cardiol 2004;43:
2142–6) © 2004 by the American College of Cardiology Foundatione
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1ccording to the National Cholesterol Education Program-
dult Treatment Panel-III (NCEP-ATP-III), the target
ow-density lipoprotein (LDL) level for patients with estab-
ished coronary disease or coronary heart disease (CHD)
isk equivalents (such as diabetes, peripheral or cerebral
ascular disease, or predicted 10-year CHD risk of 20%)
s 100 mg/dl (1). The European guidelines set the LDL
arget at 115 mg/dl (2). Accumulating data from multiple
ines of evidence consistently demonstrate that the physio-
ogically normal LDL level and the thresholds for athero-
clerosis development and CHD events are approximately
0 to 70 mg/dl.
HY AVERAGE IS NOT OPTIMAL
therosclerosis development is a complex process influ-
nced by a myriad of risk factors, although the LDL level is
mong the most important. In an atherogenic millieu,
xidized LDL infiltrates the intima where it stimulates
nflammation, endothelial dysfunction, and eventually ath-
rosclerosis. Although it is true that very high LDL levels
200 mg/dl) are strongly associated with CHD risk,
therosclerosis is not uncommon even in those with rela-
ively “normal” LDL levels (90 to 130 mg/dl) (3,4). More-
ver, the 10% of the population with the highest LDL levels
ccount for only 20% of the CHD events (3). Thus,
ocusing treatment only on those with very high cholesterol
evels will ignore 80% of the people destined to suffer a
HD event (4). The mega-trials using statin therapy have
emonstrated remarkable reductions in CHD events and in
ll-cause mortality among patients with baseline LDL levels
enerally from 120 to 180 mg/dl and on-treatment values
etween 100 and 140 mg/dl (5–11). Whereas cardiovascular
From the *Mid America Heart Institute, Cardiovascular Consultants, Kansas City,
issouri; †Department of Health and Exercise Science, Colorado State University,
ort Collins, Colorado; and the ‡University of Maryland, University of Maryland
ospital, Baltimore, Maryland.eManuscript received March 14, 2004; accepted March 15, 2004.vents were reduced by 25% in these studies, approximately
hree out of four CHD events occurred despite the statin
herapy. This 25% reduction in LDL represents only partial
reatment, and more robust reductions appear to provide
ore impressive improvements in prognosis (12).
The average total cholesterol level in American adults
oday is 208 mg/dl (corresponding to an LDL of approxi-
ately 130 mg/dl) (13). In this case, average is not normal
ecause atherosclerosis is present in up to 40% to 50% of
omen and men by age 50 (14). Atherosclerosis is endemic
n our population in part because the average person’s LDL
evel is approximately twice the normal physiologic level
Fig. 1).
We live in a world very different from that for which we
re genetically adapted. Profound changes in our environ-
ent began with the introduction of agriculture and animal
usbandry 10,000 years ago, too recent on an evolutionary
ime scale for the human genome to adjust. As a result of
his ever-worsening discordance between our ancient genet-
cally determined biology and the nutritional, cultural, and
ctivity patterns in modern populations, many of the so-
alled diseases of civilization, including atherosclerosis, have
merged. Evidence from hunter-gatherer populations while
hey were still following their indigenous lifestyles showed
o evidence for atherosclerosis, even in individuals living
nto the seventh and eighth decades of life (15,16). These
opulations had total cholesterol levels of 100 to 150 mg/dl
ith estimated LDL cholesterol levels of about 50 to 75
g/dl. The LDL levels of healthy neonates are even today
n the 30 to 70 mg/dl range. Healthy, wild, adult primates
how LDL levels of approximately 40 to 80 mg/dl (17). In
act, modern humans are the only adult mammals, excluding
ome domesticated animals, with a mean LDL level over 80
g/dl and a total cholesterol over 160 mg/dl (15,16) (Fig.
). Thus, although an LDL level of 50 to 70 mg/dl seems
xcessively low by modern American standards, it is pre-
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nd eating the diet for which we are genetically adapted.
DL AND ATHEROSCLEROSIS PROGRESSION
bundant data from prospective trials reveal a strong and
irect relationship between on-treatment LDL level and
ate of atherosclerotic progression. These randomized con-
rolled trials show that whether patients were on statin
herapy or placebo, the rate of angiographic progression of
therosclerosis was closely related to the chronic LDL level
18–24). Figure 2 indicates that the threshold for athero-
clerotic progression may be at an LDL level of approxi-
ately 67 mg/dl. The strongest data on atherosclerotic
rogression come from the Reversal of Atherosclerosis with
ggressive Lipid Lowering (REVERSAL) trial (24). In this
andomized study of 654 patients with symptomatic coro-
Abbreviations and Acronyms
CHD  coronary heart disease
LDL  low density lipoprotein
NCEP-ATP-III  Natural Cholesterol Education
Program-Adult Treatment Panel-III
igure 1. Total cholesterol levels for hunter-gatherers, wild primates, and
ow-density lipoprotein levels of about 35 to 70 mg/dl [24,25]). The mean
alues (13).ary disease and a baseline stenosis of 20% or more on
oronary angiography, patients were randomized to high-
ose atorvastatin, 80 mg daily, or pravastatin, 40 mg daily.
oronary atherosclerosis, as documented by intravascular
ltrasound, was virtually halted in the atorvastatin group
here a 48% LDL reduction led to a mean on-treatment
DL of 79 mg/dl. The pravastatin group experienced a 28%
ecline to a mean on-treatment LDL of 110 mg/dl. These
iffering regimens resulted in 0.4% regression of atheroma
olume in the atorvastatin versus a 2.7% mean progression
n the pravastatin group over the 18-month trial. Systemic
nflammation was also reduced at lower LDL levels as
eflected by the C-reactive protein levels, which were
educed by 36% in the group treated to a mean LDL of 79
g/dl compared to a 5% decrease when the LDL was 110
g/dl (24).
Two recent studies using ultrasound determined carotid
ntima-media thickness also found that aggressive LDL
eduction halted atherosclerosis, whereas moderate LDL
owering allowed for continued progression. The Atorvasta-
in versus Simvastatin on Atherosclerosis Progression
ASAP) trial compared atorvastatin 80 mg/day to simvasta-
in 40 mg/day in 325 patients with familial hypercholester-
lemia (25). Carotid intima-media thickness regressed
mammals, generally range from about 70 to 140 mg/dl (corresponding to
terol levels of modern Westernized humans are almost twice these normalwild
choles
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The Optimal LDL Is 50 to 70 mg/dl June 2, 2004:2142–6.031 mm over two years in the atorvastatin group com-
ared with a 0.036-mm progression in the simvastatin
roup. The Arterial Biology for the Investigation of the
reatment Effects of Reducing Cholesterol (ARBITER)
rial used 80 mg/day atorvastatin versus 40 mg/day prava-
tatin in 161 patients with a mean baseline LDL of 150
g/dl (26). Atorvastatin reduced LDL by 50% to a mean
DL of 76 mg/dl compared with a 27% drop to a mean of
10 mg/dl on pravastatin. Again, the carotid intima-media
hickness regressed 0.038 mm in the atorvastatin group
ompared with a mean progression of 0.026 mm in the
ravastatin group (p  0.021). Both of these trials demon-
trated the inadequacy of LDL reduction to current goals.
DL CHOLESTEROL AND CHD EVENT REDUCTION
bservational studies show a continuous positive relation-
hip between CHD risk and LDL levels that extends well
elow the average range seen in modern populations with-
ut any definite threshold where lower LDL concentrations
re not associated with lower risk (27). Over 100,000
atients have been randomized to statin therapy in CHD
vent reduction trials. When examined in aggregate, these
tudies also demonstrate a direct relationship between on-
reatment LDL cholesterol and absolute risk of CHD
vents (5–12). Trials from both the setting of primary
revention (Fig. 3) and secondary prevention (Fig. 4) show
hat the risk of suffering a CHD event during the course of
igure 2. Atherosclerosis progression varies directly with low-density
ipoprotein (LDL) cholesterol. This regression line indicates that athero-
clerosis does not progress when LDL is 67 mg/dl or below (18–24). Data
rom randomized placebo-controlled trials using statins for preventing
therosclerosis progression (analysis for Fig. 2) or preventing coronary
eart disease events in primary (analysis for Fig. 3) or secondary (analysis
or Fig. 4) prevention were utilized for computation of the univariate
egression lines correlating LDL with outcomes. Regression estimates,
odel R2, and p values for LDL effect were obtained from the unweighted
egression lines. AT  atorvastatin; CCAIT  Canadian Coronary
therosclerosis Intervention Trial; LCAS  Lipoprotein and Coronary
therosclerosis Study; MAAS  Multicentre Anti-Atheroma Study;
ARS  Monitored Atherosclerosis Regression Study; MLD  mean
uminal diameter; P  placebo; PLAC  Pravastatin Limitation of
therosclerosis in the Coronary Arteries study; PR  pravastatin; RE-
RESS  Regression Growth Evaluation Statin Study; REVERSAL 
eversal of Atherosclerosis with Aggressive Lipid Lowering; S  statin.he study was closely correlated with on-treatment LDL. Tnterestingly, the LDL level at which the cardiovascular
vent rate is predicted to approach 0 is 57 mg/dl for primary
revention and 30 mg/dl for secondary prevention. These
ata implicate LDL as a requisite catalyst in the atheroscle-
osis process whereby extremely low LDL may prevent
HD events regardless of the other risk factors.
In the Heart Protection Study (8), approximately 3,500 of
he 20,536 (17%) participants presented with a baseline
DL measurement that was below the “target” level of 100
g/dl even before initiating simvastatin or placebo. In this
ubset, the mean LDL reduction from 97 mg/dl to 65 mg/dl
n statin therapy produced a 25% reduction in relative risk
f CHD, which was similar to the benefits seen in the
atients presenting with baseline LDL levels 100 mg/dl.
The recently published PRavastatin Or atorVastatin
valuation and Infection Therapy (PROVE-IT) trial is the
trongest verification of the lower is better hypothesis (12).
his study randomized 4,162 acute coronary syndrome
igure 3. Coronary heart disease (CHD) event rates in primary prevention
rials (4 to 5 years duration) are directly proportional to the on-treatment
ow-density lipoprotein (LDL) cholesterol levels. The event rate is pre-
icted to approach 0 at an LDL level of about 57 mg/dl (5–7). AFCAPS
Air Force Coronary Atherosclerosis Prevention Study; ASCOT 
nglo-Scandinavian Cardiac Outcome Trial; WOSCOPS  West Of
cotland Coronary Prevention Study. Other abbreviations as in Figure 2.
igure 4. Coronary heart disease (CHD) event rates in secondary preven-
ion trials (5 years in duration except the PROVE-IT study, which was 2
ears) were directly proportional to low-density lipoprotein (LDL) choles-
erol levels. The event rate is predicted to approach 0 at LDL of 30 mg/dl
8–12). 4S  Scandinavian Simvastatin Survival Study; CARE  Cho-
esterol And Recurrent Events trial; HPS  Heart Protection Study;
IPID  Long-term Intervention with Pravastatin In Ischemic Disease
rial; PROVE-IT PRavastatin Or atorVastatin Evaluation and Infection
herapy trial. Other abbreviations as in Figure 2.
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June 2, 2004:2142–6 The Optimal LDL Is 50 to 70 mg/dlatients with a baseline total cholesterol of 200 mg/dl or less
ither to atorvastatin 80 mg or pravastatin 40 mg daily. The
n-treatment LDL was 62 mg/dl (51% decrease) for the
torvastatin group versus 95 mg/dl (22% decrease) for the
ravastatin group. At the end of two years, a highly
ignificant 16% reduction (p  0.001) in adverse CHD
vents and a 28% reduction in death were noted in the
torvastatin group (Fig. 5). This trial is especially relevant
ecause pravastatin-treated patients achieved a mean LDL
95 mg/dl) that was under the current target of 100 mg/dl,
et they continued to experience excess CHD events (Fig. 5).
S A TARGET LDL OF 50 TO 70 MG/DL PRACTICAL?
he newer and more potent statins are capable of dramat-
cally reducing LDL cholesterol safely and tolerably in most
atients. The Statin Therapies for Elevated Lipid Levels
ompared Across doses to Rosuvastatin (STELLAR) trial
andomized more than 3,000 patients either to rosuvastatin,
torvastatin, simvastatin, or pravastatin (28). The rosuvas-
atin (10 mg/day), atorvastatin (80 mg/day), and simvastatin
80 mg/day) all achieved the NCEP ATP-III LDL goal in
pproximately 80% of patients. Higher doses of high-
fficacy statins are more effective in reaching goals especially
hen combined with diet and agents, such as ezitimibe,
iacin, or plant sterol and stanol esters. However, today only
ne in three CHD patients is at or below the more liberal
urrent LDL goal of 100 mg/dl (29). Much work remains to
e done in the development of treatment strategies to
chieve the LDL goal of 50 to 70 mg/dl in most CHD
atients.
Some investigators have proposed that any one specific
DL threshold is artificial, and if clinically significant
therosclerosis develops, the LDL cholesterol warrants
reatment regardless of the absolute level (3). Using this
pproach, LDL reductions of 50% for secondary prevention
atients and 30% for primary prevention can be supported
igure 5. The PRavastatin Or atorVastatin Evaluation and Infection
herapy (PROVE-IT) trial randomized over 4,000 patients either to
igh-dose atorvastatin (low-density lipoprotein [LDL]  62 mg/dl) or
ravastatin (LDL  95 mg/dl) (12). A 16% reduction in the primary end
oint was noted in the atorvastatin-treated group.y the cumulative randomized trial experience (5–12).ow low is too low? Cholesterol is an essential component
f the cell membrane and an obligate precursor for bile acid,
teroid hormone, and vitamin D synthesis. Consequently, it
s likely that a physiologically ideal range of blood choles-
erol exists above and below which adverse health conse-
uences might be expected. Although individuals with
erious chronic illnesses, such as cancer, often develop
epressed LDL levels as a result of malnutrition, epidemi-
logic studies show that people with naturally low LDL
evels are associated with improved longevity (27). The
umulative experience with statin therapy shows impressive
ardiovascular benefits that are directly proportional to LDL
owering with no increase in adverse events such as malig-
ancy or non-cardiovascular mortality (5–12,18–26). The
ncidence of the two principal adverse effects commonly
ttributed to statins—liver and muscle toxicity—rise mod-
stly as a function of dose of statin utilized but not in
elationship to the on-treatment LDL level (5–12).
People with heterozygous hypobetalipoproteinemia have
otal cholesterol levels as low as 80 mg/dl and LDL
holesterol levels as low as 30 mg/dl (30). This condition is
ssociated with longevity (31), presumably due to the
bsence of atherosclerosis, but the lack of other adverse
ffects that might have accompanied a low LDL level
uggests that such low levels of LDL are safe.
nintended benefits of LDL lowering. Inflammation and
ndothelial dysfunction, both important markers of abnormal
ascular biology, have been shown to be improved as LDL is
owered to 80 mg/dl (12,24). Statin therapy has been
ssociated with reductions in the incidence of symptomatic
eripheral vascular disease (32), stroke (33), dementia (34),
acular degeneration (35), aortic stenosis (36), and
steoporosis-related hip and vertebral fractures (37). Although
he mechanisms responsible for these benefits are not known,
t is possible that an elevated LDL cholesterol level may be a
ommon denominator predisposing to a wide variety of
hronic degenerative diseases seen in modern civilization. If
ur genetically determined ideal LDL is indeed 50 to 70
g/dl, perhaps lowering the currently average but elevated
evels closer to the physiologically normal range may improve
ot just CHD but also many other diseases commonly attrib-
ted to the aging process. For all of these reasons, and given
he safety record of statins, some investigators have suggested
hat statins be considered for routine use in individuals over age
5 years (38).
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